title: Flawed Australian CD study does not end MAP controversy.
authors.forename: Judith E
authors.initials: JE
authors.lastname: Lipton
authors.forename: David P
authors.initials: DP
authors.lastname: Barash
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use; D002991:Clofazimine / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy* / Q000821:virology*; D004359:Drug Therapy, Combination; D006801:Humans; D016927:Mycobacterium avium subsp. paratuberculosis / Q000472:pathogenicity*; D010283:Paratuberculosis / Q000150:complications* / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D017828:Rifabutin / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D017828:Rifabutin; D002991:Clofazimine; D017291:Clarithromycin